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Proteasomes generate spliced 
epitopes by two different 
mechanisms and as efficiently  
as non-spliced epitopes
F. Ebstein1, K. Textoris-Taube1, C. Keller1, R. Golnik1, N. Vigneron2, B. J.  Van den Eynde2, 
B. Schuler-Thurner3, D. Schadendorf4, F. K. M. Lorenz5, W. Uckert5,6, S. Urban1, A. Lehmann1, 
N. Albrecht-Koepke1, K. Janek1, P. Henklein1, A. Niewienda1, P. M. Kloetzel1 & M. Mishto1
Proteasome-catalyzed peptide splicing represents an additional catalytic activity of proteasomes 
contributing to the pool of MHC-class I-presented epitopes. We here biochemically and 
functionally characterized a new melanoma gp100 derived spliced epitope. We demonstrate that 
the gp100mel47–52/40–42 antigenic peptide is generated in vitro and in cellulo by a not yet described 
proteasomal condensation reaction. gp100mel47–52/40–42 generation is enhanced in the presence of the 
β5i/LMP7 proteasome-subunit and elicits a peptide-specific CD8+ T cell response. Importantly, we 
demonstrate that different gp100mel-derived spliced epitopes are generated and presented to CD8+ 
T cells with efficacies comparable to non-spliced canonical tumor epitopes and that gp100mel-derived 
spliced epitopes trigger activation of CD8+ T cells found in peripheral blood of half of the melanoma 
patients tested. Our data suggest that both transpeptidation and condensation reactions contribute 
to the frequent generation of spliced epitopes also in vivo and that their immune relevance may be 
comparable to non-spliced epitopes.
CD8+ T cell responses involve in most cases the proteasome-dependent processing of antigens and cell sur-
face presentation of the resulting peptides by MHC-class I molecules to cytotoxic T lymphocytes (CTLs). The 
20S standard proteasome (s-proteasome) with its active site β -subunits β 1, β 2 and β 5, the immunoproteasome 
(i-proteasome) with the IFN-γ -induced catalytic β -subunits β 1i/LMP2, β 2i/MECL1 and β 5i/LMP7 or interme-
diate proteasome types containing both standard and immuno-subunits1,2 are the catalytic cores of 30S proteas-
omes, which are formed by the association of two 19S regulator complexes with the 20S core3. The 30S proteasome 
isoforms execute the regulated degradation of ubiquitin (Ub)-tagged proteins, thereby generating peptides pre-
sented by MHC-class I proteins4,5. Exchange of standard catalytic subunits for the corresponding IFN-γ -induced 
β -subunits leads to variations of proteasome catalytic pocket structure and of the peptide transport along the pro-
teasome inner channel6–8. Such variations may result in quantitative differences in the proteasome cleavage prod-
ucts, which in turn can strongly affect cell surface presentation of MHC-class I-bound virus- or tumor-specific 
antigenic peptides and in consequence also the efficacy of a peptide-specific CD8+ T cell response9,10.
Canonical MHC-class I-bound peptides generated by proteasomes mirror the linear sequence of the 
parental protein10. In contrast, spliced peptides that are presented by MHC-class I molecules and generated 
by proteasome-catalyzed peptide splicing (PCPS) result from the ligation of two separate distant proteasomal 
cleavage products that are not contiguous in the parental protein. We previously provided experimental proofs 
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for the hypothesis that PCPS proceeds via a transpeptidation reaction11–14. PCPS involves the formation of an 
O-acyl-enzyme intermediate consisting of a N-terminal peptide fragment linked to the Thr1 residue of one of the 
β-subunit active sites. In the course of the transpeptidation reaction, this acyl-enzyme intermediate is subjected to 
a nucleophilic attack by the amino-terminus of another peptide fragment leading to the creation of a new peptide 
containing two non-contiguous fragments of a protein11,12,15. Theoretically, spliced peptides may also be pro-
duced without the formation of a semi-stable O-acyl-enzyme intermediate by a so-called condensation reaction. 
Condensation reactions forming de novo peptide bonds have been described for some proteases to occur in vitro 
under conditions disfavoring diffusion of peptides from the active sites16,17. However, whether such a condensa-
tion reaction can take place in cellulo in the barrel-shaped proteasome controlling peptide diffusion and whether 
this can contribute to epitope production has yet to be shown.
Five spliced epitopes, derived from the fibroblast growth factor 5 (FGF-5172–176/217–220), melanocyte protein 
gp100mel (gp100mel40–42/47–52; gp100mel195–202/192), the SP100 nuclear phosphoprotein (SP100296–301/286–289) and 
tyrosinase (Tyr368–373/336–340) have been identified so far using cancer patient-derived CTLs for epitope identi-
fication11,12,18–20. Interestingly, two of these spliced peptide-specific CD8+ T cells have previously been shown 
to induce regression of tumors in a clinical setting20,21 or the engraftment of acute myeloid leukemia cells in 
non-obese diabetic/SCID mice11,22, indicating their potential immune relevance.
PCPS represents a genuine catalytic activity of proteasomes competing with the normal proteasomal hydrol-
ysis event14. Initial estimations of epitope splicing efficacy were calculated to range between 0.0002% and 0.01% 
of the total proteasome-dependent epitope generation. Therefore, epitope production by PCPS was thought to 
be an extremely rare event12,13,16. However, performing in vitro experiments we showed that PCPS may be a 
relatively frequent process controlled by certain sequence requirements guaranteeing that PCPS is also a highly 
reproducible reaction14. In fact, in vitro experiments suggested that potential MHC-class I epitopes are relatively 
more frequent among spliced peptides than among the “canonical” non-spliced proteasome cleavage prod-
ucts14,23. The limited number of spliced tumor epitopes identified most likely resides in the fact that identification 
of immune-relevant spliced peptides has so far been limited by the serendipitous availability of patient-derived 
CTLs and the concomitant considerable experimental effort to identify the cognate epitopes.
To close this gap, we here report an algorithm-aided reverse immunology approach permitting the facilitated 
identification of spliced peptides from a given protein sequence thereby overcoming the need for patient-derived 
CTLs. By applying this method we here identified a new spliced peptide derived from melanocytic protein 
gp100mel. This peptide can be generated in vitro and in cellulo by a condensation reaction. This epitope is pre-
sented by patient-derived melanoma cells and triggers activation of CD8+ T cells found in the peripheral blood 
of melanoma patients. Importantly, we show that spliced epitopes are presented at the cell surface and trigger 
CTL responses with efficacies similar to non-spliced epitope underlining that PCPS may play an important role 
in anti-tumor immune responses.
Results
The gp100mel47–52/40–42 antigenic peptide is generated by a new proteasomal catalytic mecha-
nism. For identification of new spliced peptides and/or epitopes we subjected the gp100mel-derived synthetic 
polypeptide substrate gp100mel40–52 [RTKAWNRQLYPEW] to in vitro digestion by purified human 20S proteas-
omes. By applying SpliceMet23 we identified three spliced peptides among the proteasomal processing products. 
These were the previously reported spliced antigenic peptide gp100mel40–42/47–52 [RTK][QLYPEW]12 and the novel 
gp100mel47–52/40–46 [QLYPEW][RTKAWNR] and gp10047–52/40–42 [QLYPEW][RTK] peptides (Fig. 1A, Fig. S1). 
Interestingly, a theoretical IC50 value of 86.1 μM for HLA-A*03:01 and HLA-A*011 binding was predicted for 
gp100mel47–52/40–42 [QLYPEW][RTK] by in silico analysis24. Therefore, we decided to analyze the formation of this 
potential new spliced tumor epitope in more detail.
Monitoring the in vitro generation of the spliced peptides revealed that the spliced peptide gp100mel40–42/47–52 
was produced approximately 6-fold more efficiently by erythrocytes s-proteasomes than the new spliced 
gp100mel47–52/40–42 peptide, being composed of the same peptide fragments but in reversed order (Fig. 1B). 
Interestingly, opposite to the generation kinetics of the individual splice-reactants [QLYPEW], [RTKAWNR] or 
[RTK] (Fig. 1C), spleen i-proteasomes generated the spliced peptides gp10047–52/40–46 and gp10047–52/40–42 more 
efficiently than erythrocytes s-proteasomes (Fig. 1D, Fig. S2).
Both the gp100mel47–52/40–42 and gp100mel47–52/40–46 peptides were the result of the linkage between the gp100 
Trp52 and Arg40 residues of the gp100-derived substrate (Fig. 1E). However, the Trp52 residue of the N-terminal 
splice-reactant [QLYPEW] represents the C-terminal residue of the synthetic polypeptide substrate gp100mel40–52. 
This excluded the formation of an O-acyl-enzyme intermediate with the proteasomal active site Thr1 as a result of 
peptide-bond hydrolysis as demanded for the established transpeptidation reactions12,14. We therefore hypothe-
sized that spliced peptides could also be produced in a proteasome-catalyzed condensation reaction.
To test this hypothesis we co-incubated purified 20S proteasomes with the two splice-reactant peptides 
gp100mel40–42 [RTK] and gp100mel47–52 [QLYPEW]. The resulting spliced peptide products were then ana-
lyzed by mass spectrometry. In support of our hypothesis, 20S proteasomes catalyzed the formation of the 
gp100mel47–52/40–42 peptide in vitro when the two peptides were added individually (Fig. 1E, Fig. S3). In accordance 
with the results shown in Fig. 1D i-proteasomes derived from different cellular sources catalyzed the condensa-
tion reaction with higher efficiency than s-proteasomes (Fig. 1F).
In principle, all active sites of both proteasome isoforms are capable of catalyzing a transpeptidation reaction14. 
However, because condensation reactions require specific favorable conditions16 we next asked whether any of 
the proteasome active sites were specifically involved in the condensation reaction. To do so, proteasome active 
site subunit specific inhibitors, whose active site specificity had been previously documented25 were added to 20S 
proteasomes derived from T2 cells (s-proteasome) or LCLs (i-proteasome) together with the two splice-reactants 
[RTK] and [QLYPEW]. PR-893 (0.5 μM) was used to block the activity of the β 5 subunits of 20S s-proteasomes 
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and PR-924 (0.5 μM) to inhibit the activity of the β 5i immuno-subunit25. Blockage of either the β 5 active site as 
in T2 cell-derived 20S proteasome or the β 5 and β 5i active sites as present in LCL-derived proteasomes led to a 
strong reduction of the condensation reaction (Fig. 1G). In contrast, blocking the β 1/β 1i and β 2/β 2i active sites 
with YU-102 (2 μM) and LU-102 (2 μM) proteasome inhibitors25, respectively, barely affected the production of 
the antigenic peptide, suggesting that the condensation reaction was mainly executed by the active sites of the β 5 
subunit isoforms (Fig. 1G).
Cellular condensation reaction results in the presentation of the gp100mel47–52/40–42 peptide. 
Although our in vitro experiments clearly demonstrated that proteasomes are able to generate spliced peptides 
in a condensation reaction, there still remained the possibility that the in vitro experiments as performed here 
may be artificially influenced by high enzyme and/or substrate concentrations. Therefore, to assess whether the 
gp100mel47–52/40–42 peptide is of any functional relevance and to study whether proteasomes could perform conden-
sation reactions also in cellulo we established an immunological read-out system to monitor the generation and 
MHC class I presentation of gp100mel47–52/40–42 in HeLa cells. HLA-A binding affinity assays using HLA-A*03:01- 
transfected HeLa and T2 cells lines (Fig. 2A,B) as well as mature dendritic cells (data not shown) confirmed 
the predicted binding of the peptide to HLA-A*03:01 complex. We therefore generated a gp100mel47–52/40–42 
Figure 1. Involvement of proteasome standard- and immuno-subunits in in vitro spliced peptide 
generation. (A) B- and Y-ions of the spliced products gp100mel40–42/47–52 [RTK][QLYPEW], gp100mel47–52/40–42 
[QLYPEW][RTK] and gp100mel47–52/40–46 [QLYPEW][RTKAWNR] as detected by MS/MS Orbitrap analysis 
(see also Fig. S1) and derived from gp100mel40–52 upon 20S proteasome-catalyzed digestion. (B) Erythrocyte 20S 
s-proteasomes generated larger amount of the spliced peptide gp100mel40–42/47–52 than of the gp100mel47–52/40–42 
and gp100mel47–52/40–46 peptides. (C,D) Erythrocyte 20S s-proteasomes generated similar or larger amounts 
of the splice reactants gp100mel40–42 [RTK], gp100mel40–46 [RTKAWNR] and gp100mel47–52 [QLYPEW] (C) but 
less gp100mel47–52/40–42 and gp100mel47–52/40–46 spliced peptides than spleen 20S proteasomes (D). (B–D) The 
means of the amount measured after 3 hrs in vitro digestion and the SD between triplicates of two independent 
experiments are shown. Significant differences of the means are detected by student t test and marked by *. In 
particular, (B) gp100mel: 40–42/47–52 vs 47–52/40–42, p = 0.002; 40–42/47–52 vs 47–52/40–46, p < 0.001; (C) gp100mel40–46 s- vs 
i-proteasome, p = 0.036; gp100mel47–52 s- vs i-proteasome, p = 0.043; (D) gp100mel47–52/40–42: s- vs i-proteasome 
p < 0.001; gp100mel47–52/40–46: s- vs i-proteasome p < 0.001. (E) B- and Y-ions of peptide gp100mel47–52/40–52 
-detected by MALDI-TOF/TOF-MS (Fig. S3) – that was produced by hydrolysis-independent ligation of 
the splice-reactants [RTK] and [QLYPEW] by 20S proteasome. (F) The peptide gp100mel47–52/40–42 amount, 
generated by hydrolysis-independent ligation by i- and s-proteasomes is shown. Amounts below 10 fmol could 
be detected but not quantified and are symbolized with ♦ . (G) Absolute amounts of gp100mel47–52/40–42 generated 
in the hydrolysis-independent assay by T2 and LCL 20S proteasomes in the presence of the inhibitors YU-102 
(2 μM; β 1/β 1i-specific), LU-102 (2 μM; β 2/β 2i-specific), PR-893 (0.5 μM; β 5-specific) and PR-924 (0.5 μM; 
β 5i-specific). Significant differences due to the effect of the inhibitors are detected by paired student t test and 
marked by * (T2 proteasome, control vs PR-893, p = 0.037; LCL proteasome, control vs PR-893, p = 0.050; 
control vs PR-924, p = 0.012). (F,G) The mean (fmol measured in 9 μl reaction) and the SD of independent 
experiments (n = 2–3), each measured in two duplicates are shown.
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peptide-specific CTL clone from peripheral blood mononuclear cells (PBMCs) of a HLA-A*03:01+ healthy donor 
(Fig. S4) allowing us to monitor the generation of this potential MHC class I-restricted epitope in cellulo.
To monitor the condensation reaction in cellulo, HeLaHLA-A*03:01+ cells were transfected with a plasmid 
expressing a HA-Ub-gp100mel40–52 fusion protein (HelaA*03:01+Ub/gp100mel40–52). In the fusion protein the GG motif 
of the ubiquitin was directly linked to the first amino acid residue of the 13-mer gp10040–52 peptide allowing 
the release of the unchanged full-length gp100mel40–52 peptide substrate after cleavage behind the GG motif by 
de-ubiquitinating enzymes (Fig. 2C). CTL assays using the gp100mel47–52/40–42 specific CD8+ T cell clone demon-
strated that proteasomes could indeed also perform a condensation reaction in cellulo (Fig. 2D,E), indicating that 
in addition to transpeptidation also condensation reactions may also contribute to the cellular pool of spliced 
epitopes.
The gp100mel47–52/40–42 peptide is a tumor epitope presented by melanoma cells. This data 
raised the question whether the proteasome-catalyzed generation of gp100mel47–52/40–42 was solely determined 
by the biochemical nature of the 13-mer gp100mel40–52 substrate and/or the specific assay conditions applied 
in vitro and/or in cellulo. To further validate our reverse immunology approach, we next investigated whether the 
gp100mel47–52/40–42 peptide was also naturally produced from full-length gp100mel antigen by patient-derived mela-
noma cells. Of the five different patient-derived melanoma cell lines tested for gp100mel protein and HLA-A*03:01 
expression only Mel63a cells proved to be HLA-A*03:01+/gp100mel + (Fig. 3A,B). Immunoblotting revealed that 
Figure 2. The spliced gp100mel47–52/40–42 peptide is generated from the gp100mel40–42 peptide by a 
condensation reaction in cellulo. (A,B) The spliced peptide gp100mel47–52/40–42 [QLYPEW][RTK] bound 
the HLA-A*03:01 complex on the cell surface of HeLa (A) and T2 (B) cell lines. In (A) the side / forward 
scatters charts are reported in the left panel. Cells included in the analysis are marked with a circle and their 
HLA-A*03:01 amount is shown in the right panel. (B) Shown is the binding affinity of the spliced peptide 
gp100mel47–52/40–42 compared to a known good HLA-A*03:01 – binder, i.e. [ILRGSVAHK] (NP265–273)35 and 
to the negative controls HLA-A*32:01-restricted gp100mel40–42/47–52 [RTK][QLYPEW] and HLA-A*02:01-
restricted gp100mel209–217 [IMDQVPFSV] epitopes. Cells were transfected with HLA-A*03:01 protein encoding 
plasmids and pulsed with 100 μM (A) or different peptide concentrations (B). Binding affinity was measured 
by staining of HLA-A*03:01 and FACS analysis. Values are in mean fluorescence unit (MFU) and are means 
and SD of 2 replicates in a representative assay of 2–6 independent experiments. (C) Schematic representation 
of the HA-Ub/gp100mel40–52 fusion construct used in this study. The first amino acid of the gp100mel40–52 
[RTKAWNRQLYPEW] sequence was directly fused in frame to the C-terminus of the Ub, which was 
N-terminally tagged with the YPYDVPDYA HA sequence. When expressed in cells, Ub hydrolases cleaved the 
fusion-polypeptide directly after the last amino acid (Gly76) of Ub, liberating the gp100mel40–52 peptide from the 
first residue. (D) CTL response towards HeLa 33/2 cells transfected with HLA-A*03:01 individually or together 
with HA-Ub/gp100mel40–52 for 24 hrs. Their ability to present gp10047–52/40–42 epitope was measured by using 
K631 1C CTL. After 16 hrs co-culture, the IFN-γ concentration in supernatants was determined by ELISA. 
Values are means and SD of 2 replicates in a representative assay of 6 independent experiments. Significant 
differences in the means of replicates are marked by * (student t-test; E:T ratio: 1:1, p = 0.003; 2:1, p = 0.050). 
(E) 10 μg of whole HeLa 33/2 cell extracts were resolved on a 15% SDS-PAGE for western blotting with anti-HA 
antibody to control the expression of the construct. The western blot is representative of 5 independent assays.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:24032 | DOI: 10.1038/srep24032
Mel63a cells mostly expressed intermediate-type proteasomes, expressing all standard and IFN-γ inducible pro-
teasome subunits except the β 2i subunit (Fig. 3B). Interestingly, the Mel63a cells elicited a strong IFN-γ release 
by the gp100mel47–52/40–42 specific T-cell clone, suggesting that the spliced peptide gp100mel47–52/40–42 can indeed 
be produced from the full-length gp100mel protein (Fig. 3C). This proved that the spliced gp100mel47–52/40–42 pep-
tide identified by applying SpliceMet in in vitro experiments represented a natural tumor epitope produced 
from the full-length gp100mel membrane protein and was presented on the surface of gp100mel/HLA-A*03:01+ 
patient-derived melanoma cells.
The gp100mel47–52/40–42 epitope is generated by the ERAD pathway. To exclude the possibility that 
generation of the gp100mel47–52/40–42 peptide was restricted to a specific cell type and to study the contribution 
of individual proteasome subunits in the production of the peptide, HeLa cells were transfected with plasmids 
encoding the HLA-A*03:01 protein and a full-length gp100mel-myc/His fusion protein. As shown in Fig. 4A, HeLa 
cells efficiently presented the gp100mel47–52/40–42 epitope in a proteasome-dependent manner providing evidence 
that epitope generation was not dependent on a specific cell type. The in vitro experiments had indicated a driving 
role for the two different β 5 subunits in the generation of the gp100mel47–52/40–42 epitope (see Fig. 1F,G). To study the 
role of the β 5-subunit isoforms in a cellular context, we monitored gp100mel47–52/40–42 epitope presentation in HeLa 
33/2 cells, which constitutively express i-proteasomes, using a siRNA approach. The siRNA-induced silencing of 
β 5i subunit expression resulted in its substitution by the standard β 5 subunit within the 20S proteasome complex 
(Fig. 4B). This subunit substitution led to a remarkable reduction of gp100mel47–52/40–42 presentation underlining the 
importance of the β 5i subunit for this splicing reaction (Fig. 4B). Corroborating this result, over-expression of 
the β 5i subunit in HeLa cells and concomitant formation of β 5i/ β 1/β 2 subunits containing intermediate type 20S 
proteasomes led to a strong increase in gp100mel47–52/40–42 presentation (Fig. 4C). Interestingly, the proteasome 
subunit composition found in Hela cells overexpressing β 5i subunit was similar to that observed in Mel63a cells 
suggesting that the intermediate type proteasomes carrying β 5i, β 2 and β 1 subunits are best equipped for the 
generation and presentation of this spliced epitope.
Because gp100mel is a membrane protein we also asked whether generation of the gp100mel47–52/40–42 epitope 
from gp100mel protein resulted from the ER-associated ubiquitin-dependent protein degradation pathway 
(ERAD). To test this, expression of the ubiquitin-receptor subunit Rpn10 residing in the 19S complex and of the 
ERAD component p97/VCP were silenced by siRNA. As shown in (Fig. 4D) silencing of either Rpn10 or p97/
VCP expression significantly impaired the endogenous gp100mel47–52/40–42 epitope presentation providing evidence 
that PCPS takes place as part of normal ubiquitin-dependent protein degradation and can also involve the ERAD 
pathway.
PBMCs of melanoma patients harbor spliced epitope-specific T cells. Because the gp100mel47–52/40–42 
epitope had been identified using an open unbiased algorithm-aided reverse immunology approach, the possi-
bility still remained that its identification and generation may have been the result of the experimental set ups. 
Hence, it was important to validate whether the gp100mel47–52/40–42 peptide was also generated in vivo and that 
melanoma patients possessed CD8+ T cells directed against this epitope.
For proof of principal, we therefore tested whether HLA-A*03:01+ melanoma patients possessed CD8+ T 
cells directed against the gp100mel47–52/40–42 peptide (Fig. 5A) and/or the HLA-A*03:01-restricted spliced peptide 
gp100mel195–202/192 [RSYVPLAH][R] (Fig. 5B), which was previously shown to trigger a T cell response in mel-
anoma patients18. In total, PBMCs from 20 randomly chosen melanoma patients and 4 healthy controls were 
analyzed. Interestingly, 6/12 untreated patients and 2/8 vaccinated patients displayed T cells reactive against the 
gp100mel47–52/40–42 epitope (Fig. 5A). Only 1 out of 4 healthy controls had a measurable specific response toward 
Figure 3. Melanoma Mel63a cells efficiently generate and present the gp100mel47–52/40–42 epitope.  
(A) Overlay histograms obtained by flow cytometry showing the cell surface expression of the HLA-A*03:01 
molecule (thick line) compared to isotype control (thin line) of the Mel63a melanoma cell line. Shown is a 
representative staining of 2 independent experiments. (B) The four melanoma cell lines Mel15a, Mel18, Mel21a 
and Mel63a were analyzed by western blotting for their content of gp100mel, the proteasome subunits β 1, β 2, 
β 5, β 1i, β 2i, β 5i and α 6 (the latter as loading control). HeLa cells and HeLa 33/2 cells were used as controls for 
s- and i-proteasomes, respectively. (C) The four melanoma cell lines Mel15a (HLA-A*03:01−/gp100+); Mel18 
(HLA-A*03:01−/gp100mel+), Mel21a (HLA-A*03:01−/gp100mel−) and Mel63a (HLA-A*03:01+/gp100mel+) 
were assessed for their ability to present the gp100mel47–52/40–42 epitope in a 16 hrs CTL assay to K631 1C CTL 
clone. Supernatants were collected and tested for their IFN-γ content by ELISA. Values are means and SD of 2 
replicates in a representative assay of 2 independent experiments.
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the same spliced epitope (Fig. 5A), as further confirmed by FACS analysis (Fig. 5C). On the other hand, 5/6 
untreated and 2/8 vaccinated melanoma patients contained T cells recognizing the gp100mel195–202/192 peptide 
(Fig. 5B). This data demonstrated that our algorithm-based reverse immunology approach is a potent strategy to 
identify new spliced epitopes. They also suggested that proteasome-catalyzed generation of spliced antigenic pep-
tides is not an isolated singular event but is part of the physiological proteasome-dependent epitope generation 
process, which elicits specific CD8+ T cell responses in vivo in melanoma patients.
Spliced and non-spliced epitopes are presented at the cell surface in comparable amount. 
Despite being an important issue in judging the immune relevance of spliced epitopes, there exists no study com-
paring the relative presentation efficacy of different spliced epitopes with each other or with non-spliced epitopes. 
The gp100mel antigen seemed be ideally suited for such an analysis because the spliced peptides gp100mel47–52/40–42 
(HLA-A*03:01), gp100mel40–42/47–52 (HLA-A*32:01), gp100mel195–202/192 (HLA-A*03:01) and the non-spliced 
gp100mel209–217 (HLA-A*02:01) were all generated from the same protein. To extend the analysis to a second 
and gp100mel-independent non-spliced epitope we also included the tumor-associated HLA-A*02:01-restricted 
epitope NY-ESO-1157–16526 into the comparison. However, to perform such comparison, different HLA-A peptide 
binding affinities, HLA expression levels as well as the different affinities of the CD8+ T cells have to be taken into 
consideration.
Figure 4. Ub-proteasome- and ERAD-dependent gp100mel47–52/40–42 epitope production is enhanced by β5i 
subunit. (A) HeLa cells were transfected with HLA-A*03:01 and gp100mel, and were subjected to epoxomicin 
treatment (250 nM; 2 hrs) or DMSO (control) and compared to HeLa cells transfected with HLA-A*03:01 
treated with epoxomicin (250 nM; 2 hrs) and pulsed with the synthetic peptide gp100mel47–52/40–42 (50 μM). Values 
are means and SD of 2 replicates in a representative assay of 2 independent experiments. Significant differences 
(between the samples with or without epoxomicin) in the means of replicates are marked by * (student t-test; 
E:T ratio: 1:1, p = 0.002; 2:1, p = 0.001; 4:1, p < 0.001; 8:1, p < 0.001). (B) HeLa 33/2 cells were exposed to β 5i 
subunit or control siRNAs (30 nM for 24 hrs) and subsequently transfected with gp100mel. Cell extracts were 
analyzed by western blotting (representative of 4 independent experiments). β 5i subunit-depleted HeLa 33/2 
cells were subjected to a 16 hr CTL assay. Values are means and SD of 2 replicates in a representative assay of 
4 independent experiments. Significant differences in the means of replicates are marked by * (student t-test; 
p = 0.047). (C) HeLa cells were transfected with plasmids encoding HLA-A*03:01, gp100mel full-length protein, 
β 5i subunit or the empty vector. The HeLa cell ability to process the gp100mel47–52/40–42 was assessed by CTL assay. 
Values are means and SD of 2 replicates in a representative assay of 4 independent experiments. Significant 
difference in the means of replicates is marked by * (student t-test; p = 0.001). (D) HeLa cells were exposed to 
30 nM siRNA specific for the 19S Rpn10 subunit or p97/VCP (or control siRNA) prior to transfection with the 
HLA-A*03:01 and the full-length gp100mel protein plasmids and pulsed or not pulsed with the synthetic peptide 
gp100mel47–52/40–42 (30 μM). Values are means and SD of 2 replicates in a representative assay of 3 independent 
experiments. Significant differences in the means of replicates are marked by * (student t-test) for Rpn10 siRNA 
(E:T ratio: 1:1, p = 0.038; 2:1, p = 0.029; 4:1, p = 0.047; 8:1, p = 0.002) and for p97/VCP siRNA (E:T ratio: 
1:1, p = 0.016; 2:1, p = 0.020; 4:1, p = 0.024; 8:1, p = 0.001). The knock-down efficiencies were monitored by 
determining the steady-state level of Rpn10 or p97/VCP proteins by western blotting.
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Therefore we first performed titration experiments with HeLa cells expressing the target HLA-A molecules, 
pulsed with the antigenic peptides and co-cultivated them with the respective peptide-specific CD8+ T-cell 
clones (Fig. 6A–E upper panels). By measuring the resulting IFN-γ release, informative titration curves where 
obtained for all antigenic peptides (Fig. 6B–E) but the non-spliced gp100mel209–217 epitope (data not shown). 
Because gp100mel209–217 is known be a poor HLA-A*02:01 binder, we consequently performed the titration exper-
iments with the previously described M210 gp100mel209–217 peptide, in which the anchor residue T210 of gp100mel was 
exchanged with a Methionine for better HLA-A *02:01 binding. T cell assays were performed with transduced 
CD8+ T cells expressing the corresponding TCR. In this case satisfactory titration curves were obtained (Fig. 6A). 
We next transfected HeLaHLA-A*03:01+ cells with plasmids encoding the M210gp100mel variant, or the NY-ESO-1 
proteins together with the three HLA-A*32:01, -A*02:01 and -A*03:01molecules. The transfected cells were then 
tested for their ability to activate CD8+ T-cells specific for each of the peptides as outlined above (Fig. 6A–E lower 
panels).
We considered the measured IFN-γ release obtained with an 4:1 E:T ratio and determined the corresponding 
peptide concentrations on the basis of the titration experiments. We chose the 4:1 E:T ratio to obtain IFN-γ release 
values in the log-phase of the titration curves. By applying this method we obtained a semi-quantitative comparison 
of the amount of non-spliced vs spliced epitopes generated by proteasomes of HeLa cells and presented by MHC class 
I molecules and. As shown in Fig. 6F the amounts of the spliced gp100mel40–42/47–52 epitope and of the non-spliced 
epitope M210gp100mel209–217 were comparable and the amounts of the spliced gp100mel40–42/47–52 epitope exceeded 
those of all other epitopes analyzed. In contrast, cell surface expression of the new spliced gp100mel47–52/40–42 epitope 
was significantly lower, which is in agreement with our observation that s-proteasomes produce only relatively low 
amounts of the gp100mel47–52/40–42 epitope. Interestingly, also the expression of the non-spliced NY-ESO-1157–165 
epitope was lower than that of the gp100mel40–42/47–52 and T210Mgp100mel209–217 epitopes and comparable with the 
Figure 5. IFN-γ responses to the gp100mel47–52/40–42 and gp100mel195–202/192 spliced peptides in HLA-A*03:01+ 
healthy controls and melanoma patients. PBMCs from healthy controls and patients with melanoma 
vaccinated or not with dendritic cells pulsed with the gp100mel209–217 peptide were cultured in 96-well plates 
and stimulated with 30 μM gp100mel47–52/40–42 (A) or gp100mel195–202/192 (B) synthetic peptides. After 10 days of 
culture, the presence of CTLs specific for gp100mel47–52/40–42 and gp100mel195–202/192 epitopes in each well was 
assessed by re-stimulating the cells with the gp100mel47–52/40–42 or gp100mel195–202/192 peptide in a 16 hr assay in 
the presence of CD28/CD49d co-stimulatory molecules. A negative control without peptide was included in all 
experiments. After 16 hrs, supernatants were collected and tested for their IFN-γ content by ELISA. Shown is 
the number of wells per plate in which the IFN-γ secretion upon peptide stimulation was larger than 100 pg/ml 
and at least twice as large as that detected without peptide for each patient and/or control. (C) Validation of the 
ELISA outcome on the representative healthy control well showing the larger IFN-γ response by CD8+ T cells 
in presence of the target spliced epitope. CTLs were double stained for CD8 and intracellular IFN-γ by FACS 
analysis. The side/forward scatters chart is reported in the left panel. Cells included in the analysis are marked 
with a circle and are shown in the two right panels, where CTLs were co-cultivated for 16 hrs with antigen 
presenting cells pulsed or not pulsed with the 30 μM gp100mel47–52/40–42 synthetic peptide prior the FACS analysis.
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spliced gp100mel195–202/192 epitope, requiring C-terminal trimming. As a control, we compared the CD8+ T-cell 
response towards gp100mel40–42/47–52 and gp100mel47–52/40–42 epitopes in HeLa cells expressing the wild-type gp100mel 
and the mutated T210Mgp100mel proteins in two independent experiments. No difference emerged confirming that the 
use of the T210Mgp100mel variant did not affect the generation of the distant spliced epitopes (Fig. S5).
In summary, these experiments demonstrate that generation and presentation of spliced epitopes occurs with 
efficacies similar to what is observed for canonical non-spliced epitopes and do not represent exceptions with 
respect to their immune relevance.
Discussion
Generation of spliced epitopes is an additional proteasome-dependent activity, contributing to the pool of 
MHC-class I presented antigenic peptides. A number of features of the proteasome-dependent splicing events 
Figure 6. The processing efficacy of the gp100mel–derived spliced epitopes is comparable to that of the non-
spliced M210gp100mel209–217 and NY-ESO-1157–165 epitopes. (A–E) The IFN-γ -release by specific CD8+ T cell clones 
exposed to HLA-A*03:01/-A*02:01/-A*32:01+ HeLa cells (E:T = 1:1) pulsed with different concentrations of the 
synthetic peptides (upper panels) or HLA-A*03:01/-A*02:01/-A*32:01+ HeLa cells transfected with the target 
antigen (lower panels) is shown for the epitopes M210gp100mel209–217 (A), NY-ESO-1157–165 (B), gp100mel40–42/47–52 
(C), gp100mel47–52/40–42 (D) or gp100mel195–202/192 (E). The data are the mean and bars the SD of three replicates of a 
representative assay of independent experiments (n = 2–6). (F) We here report a marker of the amount of epitope 
presented on the cell surface of HLA-A*03:01/-A*02:01/-A*32:01+ HeLa cells transfected with the target antigen. 
By titrations (upper panels in A–E) we calculated the amount of synthetic peptide pulsed on to HeLa cells, which 
triggered the release of IFN-γ amount corresponding to the IFN-γ released by the specific CD8+ T cell clones 
exposed to HLA-A*03:01/-A*02:01/-A*32:01+ HeLa cells transfected with the target antigen and cultivated in 
an E:T ratio = 4:1 (see lower panels in A–E). Values are the means and bars the SEM of independent experiments 
(n = 2–7; each experiment with three independent replicates). Significant differences in the means are marked and 
the corresponding by p values are reported (we applied the Mann-Whitney test with Bonferroni correction for 
multiple comparison). The IFN-γ -release in the medium was measured by ELISA after 16 hrs co-culture.
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indicate that peptide splicing is not an accidental side reaction of proteasome activity but rather an authentic 
post-translational modification. One important aspect of PCPS is the fidelity of the process because to trigger 
a CD8+ T cell response a spliced peptide must be repeatedly generated from a given substrate protein. Thus, 
for a functional purpose of the resulting splicing products PCPS must be a finely tuned event27. However, a 
proteasome-catalyzed splicing event is difficult to detect because it requires the complementary information on 
gene sequence and processing events. Because of that, spliced epitopes have so far escaped wide spread identifi-
cation using available databases in combination with mass spectrometric analyses. We here applied an algorithm 
aided reverse immunology approach, which a priori does not rely on available patient-derived CD8+ T cells and 
therefore greatly facilitates the identification of new spliced epitopes.
As part of our analyses the spliced gp100mel47–52/40–42 peptide was identified as a new HLA-A*03:01-restricted 
tumor epitope expressed on patient-derived gp100mel+ melanoma cells. Interestingly, the gp100mel47–52/40–42 peptide 
was generated in vitro from the same gp100mel40–52 13-mer polypeptide substrate as the previously reported spliced 
gp100mel40–42/47–52 epitope12 but with the same peptide fragments being arranged in reverse order. This disclosed 
that in addition to the well-established transpeptidation reaction11,12,14 PCPS could also involve condensation 
reactions that in vitro are independent of prior proteasomal peptide-bond hydrolysis. Production of the spliced 
antigenic peptide in a condensation reaction could also be observed in cellulo when the 13-mer gp100mel40–52 
polypeptide substrate was expressed in HeLa cells as part of an ubiquitin fusion protein. Condensation reactions 
performed by proteinases have only been reported to occur in vitro under defined diffusion-limiting conditions. 
The gated barrel-shaped catalytic cavity of the 20S proteasome hindering rapid diffusion of the generated peptide 
as well as the catalytic activity of Thr1 via the formation of an ester-bond intermediate may however explain why 
proteasomes are able to perform condensation reactions also in a cellular environment with relative efficacy. In 
fact, in case the peptide ligands are held in the right orientation in close proximity, this does not even require 
catalysis. It is however not possible to determine the extent to which condensations reactions participate in cellulo 
to the overall production of the gp100mel47–52/40–42 peptide from the full-length gp100mel protein.
Theoretically, only relatively few MHC-class I-peptide complexes have to be exposed at the cell surface to 
trigger an immune response28 and T cells directed against spliced epitopes have been identified among a subset 
of tumor infiltrating lymphocytes10. Nevertheless, the notion that spliced epitopes represented a curiosity still 
prevailed and doubts remained whether PCPS was a sufficiently frequent event to play any significant role in 
MHC class I-restricted immune responses. Importantly, PCPS does not randomly produce an unlimited number 
of all theoretically possible spliced peptides14,23. Rather, PCPS seemed to be restricted by certain sequence char-
acteristics of the substrate protein, guaranteeing a high reproducibility in the generation of spliced epitopes14. 
But similar to the well-characterized proteasome-generated non-spliced epitopes for which reliable rules are still 
missing, general sequence rules governing spliced epitope generation are so far unresolved.
An important issue with respect to their immune relevance and a still unresolved question was whether 
spliced epitope presentation is at all comparable with that of non-spliced conventional tumor epitopes. 
Therefore, in a semi-quantitative analysis we also compared for the first time the relative efficacy of endogenous 
presentation of three different gp100mel derived spliced epitopes with that of two non-spliced tumor epitopes. 
Relative cell surface presentation efficacy of the three gp100mel derived spliced epitopes analyzed here differed 
considerably among each other. In particular, cell surface expression of the spliced gp100mel40–42/47–52 epitope 
was significantly superior to the presentation of the newly identified gp100mel47–52/40–42 epitope, which is com-
posed of the same splice-reactants but in reverse order. This difference may be explained in that the reverse 
order peptide-ligation by either transpeptidation or condensation is less efficient and/or that the generation of 
the gp100mel47–52/40–42 epitope is not favored by s-proteasomes. Importantly, our data show for the first time that 
the overall relative cell surface expression levels of the spliced epitopes is comparable to that of the non-spliced 
gp100mel209–217 and NY-ESO-1157–165 epitopes. This suggests that with regard to their relative presentation efficacy 
proteasome-generated spliced epitopes exert features almost identical to those known for non-spliced epitopes 
and do not greatly differ from what is known for canonical epitopes.
Considering that the spliced gp100mel47–52/40–42 epitope was identified in an unbiased reverse immunology 
approach and the fact that the PBMCs from approximately 50% of randomly chosen untreated melanoma 
patients contained CD8+ T cells that were stimulated by the gp100mel47–52/40–42 peptide suggested that generation 
of spliced epitopes is indeed a rather frequent event. Corroborating this result, five out of six untreated patient 
samples turned out to contain memory CD8+ T cells responsive to the spliced HLA-A*03:01-restricted epitope 
gp100mel195–202/191 [RSYVPLAH][R] that had initially been identified through the analysis of tumor infiltrating 
lymphocytes18. That a fewer number of samples obtained from melanoma patients having undergone vaccina-
tion with dendritic cells were responsive to the spliced antigenic peptides might be owed to the fact that they 
contained a relatively larger percentage of T cells directed against the non-spliced peptides, which were used for 
vaccination. Although our assay conditions are not designed to prime naïve T-cells in that dendritic cells were 
in low number and not activated, we can not completely exclude that the immune response towards the spliced 
epitopes may in part be due to priming and the activation of naïve CD8+ T cells during the in vitro assays
Supporting the conclusion that generation of MHC-class I ligands by PCPS was not a rare event, we also 
identified, by applying our SpliceMet-supported reverse immunology approach, a significant number of potential 
spliced epitopes derived from human gp100mel or Listeria monocytogenes LLO antigens and with high HLA-A 
and/or -B binding affinity, which warrant further immunological characterization (Table 1).
Our data also demonstrated that PCPS is intrinsically linked to ubiquitin-dependent proteasomal protein 
turnover and proteasomal hydrolysis events and that it was not a rare side reaction. Since peptide exhibiting 
features suitable for binding to MHC class I molecules seem to occur in among spliced peptides with a certain 
preference14, the relative probabilities for generation of a spliced epitope or a non-spliced epitope from a given 
substrate are most likely not very different. Therefore, the pool of spliced antigenic peptides available for selection 
by the antigen presentation machinery may be significantly larger than previously estimated. In fact, as shown 
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here for the gp100mel protein PCPS also seems to enlarge the HLA haplotype-restriction of antigenic peptides that 
can be produced from a single substrate protein thereby broadening the cellular immune response.
Materials and Methods
A detailed Material and Method section is disclosed in the Supplementary information.
Peptide synthesis and quantification. The sequence enumeration for the polypeptides gp10040–52 
[RTKAWNRQLYPEW], gp100mel209–217 [IMDQVPFSV], gp100mel195–202/92 [RSYVPLAH][R] are referred to the 
human protein gp100PMEL17, for the peptide [SLLMWITQC] to the NY-ESO-1 human protein. All peptides 
were synthesized as described elsewhere23. LC-MS analyses were performed as previously described14. Database 
searching was performed using the SpliceMet’s ProteaJ algorithm23. Quantification of proteasome-generated 
non-spliced and spliced peptides (Fig. 1, Fig. S2) was carried out by applying the QME method to LC-MS analy-
ses as described elsewhere14. For semi-quantitative studies of the amount of the two spliced peptides [QLYPEW]
[RTK] and [RTK][QLYPEW] (Fig. 1F,G), the heavy peptides QLYPE+6WRTK and RTK+6QLYPEW were used as 
internal standards. The limit of quantification was set to 10 fmol upon preliminary experiments with synthetic 
peptide titration
In vitro processing of synthetic peptides. The synthetic peptide gp100mel40–52 (40 μM) was digested 
by 3 μg 20S proteasomes in 100 μl TEAD buffer over time at 37 °C. In the in vitro hydrolysis-independent 
proteasome-mediated experiments (Fig. 1F,G) 5 μg 20S proteasomes were incubated in 100 μl TEAD buffer 
in presence of 100 μM peptides for 20 hours. For the experiments with the inhibitor PR-893, PR-924 (Onyx 
Pharmaceuticals, US), YU-102 and LU-10225 the specific binding to the proteasome subunits was monitored.
20S proteasome purification. 20S proteasomes were purified from LCLs and T2 cell line as previously 
described29. 20S proteasome purified from human erythrocytes and spleen were purchased from BioMol.
Cell culture. Cells used in this study include LCLs, T2 cells, HeLa cells, HeLa 33/2 cells which were all 
previously described9,30,31. The melanoma cell lines Ma-Mel15a, Ma-Mel18, Ma-Mel21a and Ma-Mel63a were 
established from tumor metastasis and grown in RPMI 1640 with 10% FCS, 1% L-glutamine and 1% penicillin. 
The CTL clones K631 1C specific for the HLA-A*03:01-restricted gp100mel47–52/40–42 epitope and RG39 specific 
for the HLA*02:01-restricted NY-ESO-1157–165 epitope were prepared according to the procedure of Fonteneau 
et al.32. The LG2-37.7.14 and M45-3B CD8+ T cell clones specific for the HLA-A*32:01-restricted 
gp100mel40–42/47–52 and HLA-A*03:01-restricted gp100mel195–202/192 spliced peptides, respectively were described 
elsewhere12,18. The gp100mel-specific TCR-transduced T cells were generated as previously described33,34.
Spliced peptide Sequence HLA-A and/or -B (IC50, nM)
substrate gp100mel35–57 –VSRQLRTKAWNRQLYPEWTEAQR
gp100mel35–39/35–39 [VSRQL] [VSRQL] B*27:05 (148)
gp100mel45–52/35–37 [NRQLYPEW][VSR] A*31:01 (38)
gp100mel47–52/40–42 [QLYPEW][RTK] A*03 (86)
gp100mel49–52/35–39 [YPEW][VSRQL] B*07:02 (18)
substrate gp100mel201–230 –AHSSSAFTITDQVPFSVSVSQLRALDGGNK
gp100mel201–207/201–207 [AHSSSAF][AHSSSAF]
A*24:03 (11), B*15:01 (120), B*15:03 
(113)
gp100mel210–218/220–222 [TDQVPFSVS][SQL] B*07:02 (94), B35:01 (182), B39:01 (133)
substrate LLO291–317 –AYISSVAYGRQVYLKLSTNSHSTKVKA
LLO291–293/295–302 [AYI][SVAYGRQV] B*15:17 (31)
LLO291–294/297–304 [AYIS][AYGRQVYL]
A*02:02 (199), A*02:11 (89), A*02:50 
(115), B*15:17 (50).
LLO291–298/291–292 [AYISSVAY][AY]
A*01:01 (121), A*29:02 (8), A*30:02 (20), 
A*68:01 (68), A*80:01 (38), B*15:01 (66), 
B*15:03 (100), B*35:01 (22)
LLO291–298/291–293 [AYISSVAY][AYI] A*30:01 (145), B*15:17 (52), B*58:01 (25)
LLO299–304/291–293 [GRQVYL][AYI] B*27:05 (99)
Table 1. Potential proteasome-catalyzed spliced antigenic peptides derived from human gp100mel35–57, 
gp100mel201–230 and LLO291–317 substrates and identified by a reverse immunology approach. Proteasome-
generated spliced epitopes were identified by applying SpliceMet23 on the proteasome-mediated digestion 
of the synthetic substrates gp100mel35–57, gp100mel201–230 and Listeria monocytogenes LLO291–317 as previously 
reported14. Afterwards, the spliced antigenic peptide list was analyzed for binding affinity to human MHC 
variants using the web-available ANN algorithm24. In agreement with our experience, only spliced epitopes 
with IC50 < 200 nM were considered as potential epitopes. We included in the list the N-terminal-extended 
precursors of the potential minimal epitopes. For each potential proteasome-catalyzed spliced epitope the 
human HLA variant and the predicted IC50 (nM) are disclosed.
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HLA-A03:01-peptide binding affinity. Binding affinity of synthetic peptides were computed with dif-
ferent peptide concentration in a standard binding affinity assay measured by flow cytometry as described else-
where29, using HeLa or T2 cells transfected with the HLA-A*03:01-expressing plasmid.
Plasmid and siRNA transfection. Expression vectors used in thy study include the pcDNA3.1 
(HLA-A*02:01, HLA-A*32, β 5i), pcDNA3.1/myc-HIS (gp100mel, NY-ESO-1) and the pcDNA3.1(+)/Zeo 
(HLA-A*03:01, HA-Ub/gp100mel40–52) plasmids. Transfection of HeLa and 33/2 cells or T2 cells was performed 
using Lipofectamin2000 or Amaxa-Nucleofactor technology, respectively, according to the manufacturer’s 
instructions. All siRNA (control, Rpn10 and p97/VCP) used in this study were purchased from Dharmacon and 
introduced into HeLa or 33/2 cells as previously described31.
Antibodies and western blotting. Cell extracts were prepared as previously described31. Proteins were 
resolved by SDS-PAGE and blotted with β 1i, β 2i, β 5i, β 1, β 2, β 5, α 6 proteasome subunits, Rpn10, HA, gp100mel, 
p97/VCP and β -actin (as a loading control).
CTL assays and screening of gp10047–52/40–42-specific CD8+ T cells in HLA-A*03:01 healthy 
donors’ and melanoma patients’ PBMCs. Targets cells were serially diluted and co-cultured with a 
fixed amount of T cells, resulting in graded effector-to-target (E:T) ratio for 12 h prior to the measurement of 
IFN-γ release by ELISA. PBMCs from healthy donor or patients with melanoma were pulsed with 30 μM of the 
gp100mel47–52/40–42 synthetic peptide in RPMI medium supplemented with 8% human AB serum, 1% penicillin 
and IL-2 (50 U/ml). After 10 days of culture, their capacity to produce IFN-γ in response to the cognate peptide 
was measured by ELISA.
Statistical Analysis
Data were tested for normality distribution and homoscedasticity by Kolmogorov-Smirnov, Shapiro-Wilk and 
Levene tests. To identify significant difference between groups reported in Fig. 6, Kruskal-Wallis followed by 
Mann-Whitney tests with Bonferroni Post Hoc correction for multiple comparisons were applied. Otherwise, 
paired and unpaired Student t-tests were carried out. Descriptive statistics were carried out with SPSS (version 
17) and R; a p-value < = 0.05 was considered statistically significant.
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